Cargando…

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value

Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoons, E., Dijkgraaf, M. G. W., Dijk, J. M., van Schaik, I. N., Tijssen, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506193/
https://www.ncbi.nlm.nih.gov/pubmed/22552527
http://dx.doi.org/10.1007/s00415-012-6510-x
_version_ 1782250866348130304
author Zoons, E.
Dijkgraaf, M. G. W.
Dijk, J. M.
van Schaik, I. N.
Tijssen, M. A.
author_facet Zoons, E.
Dijkgraaf, M. G. W.
Dijk, J. M.
van Schaik, I. N.
Tijssen, M. A.
author_sort Zoons, E.
collection PubMed
description Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20–50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47–50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00415-012-6510-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3506193
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-35061932012-11-28 Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value Zoons, E. Dijkgraaf, M. G. W. Dijk, J. M. van Schaik, I. N. Tijssen, M. A. J Neurol Review Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20–50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47–50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00415-012-6510-x) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-05-03 2012 /pmc/articles/PMC3506193/ /pubmed/22552527 http://dx.doi.org/10.1007/s00415-012-6510-x Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Zoons, E.
Dijkgraaf, M. G. W.
Dijk, J. M.
van Schaik, I. N.
Tijssen, M. A.
Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title_full Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title_fullStr Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title_full_unstemmed Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title_short Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
title_sort botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506193/
https://www.ncbi.nlm.nih.gov/pubmed/22552527
http://dx.doi.org/10.1007/s00415-012-6510-x
work_keys_str_mv AT zoonse botulinumtoxinastreatmentforfocaldystoniaasystematicreviewofthepharmacotherapeuticandpharmacoeconomicvalue
AT dijkgraafmgw botulinumtoxinastreatmentforfocaldystoniaasystematicreviewofthepharmacotherapeuticandpharmacoeconomicvalue
AT dijkjm botulinumtoxinastreatmentforfocaldystoniaasystematicreviewofthepharmacotherapeuticandpharmacoeconomicvalue
AT vanschaikin botulinumtoxinastreatmentforfocaldystoniaasystematicreviewofthepharmacotherapeuticandpharmacoeconomicvalue
AT tijssenma botulinumtoxinastreatmentforfocaldystoniaasystematicreviewofthepharmacotherapeuticandpharmacoeconomicvalue